Epaminurad
As of the edition of 20 October 2026, Epaminurad is a small molecule: of no established status; acts on SLC22A12.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Small molecule
- Registered trials
- 5, 0 stopped early
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC22A12 | Solute carrier family 22 member 12 | Q96S37 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| JW Pharmaceutical | Lead sponsor of trials | 2023 to now |